CAJ | 학술논문

目的：探讨阿德福韦酯片结合替比夫定治疗乙肝肝硬化的临床效果与安全性。方法选取2012年6月～2014年2月接受治疗的120例乙肝肝硬化患者为研究对象，按随机数表法分为对照组（n ＝60）与观察组（n ＝60）。对照组行替比夫定治疗，观察组行阿德福韦酯片结合替比夫定治疗，比较两组的肝功能与肝纤维化指标变化情况，HBV 转阴率与 HBeAg 血清转换率情况及不良反应发生情况。结果治疗后，两组各项肝功能与肝纤维化指标均降低，但观察者降低幅度大于对照组，差异具有统计学意义（P ＜0.05）；观察组 HBV 转阴率为88.3%（53/60），高于对照组的73.3%（44/60）（P ＜0.05）；观察组 HBeAg 血清转换率为13.3%（8/60），低于对照组28.3%（17/60）（P ＜0.05）。结论阿德福韦酯片结合替比夫定治疗乙肝肝硬化临床效果显著，能有效抗病毒，且不良反应少。
목적：탐토아덕복위지편결합체비부정치료을간간경화적림상효과여안전성。방법선취2012년6월～2014년2월접수치료적120례을간간경화환자위연구대상，안수궤수표법분위대조조（n ＝60）여관찰조（n ＝60）。대조조행체비부정치료，관찰조행아덕복위지편결합체비부정치료，비교량조적간공능여간섬유화지표변화정황，HBV 전음솔여 HBeAg 혈청전환솔정황급불량반응발생정황。결과치료후，량조각항간공능여간섬유화지표균강저，단관찰자강저폭도대우대조조，차이구유통계학의의（P ＜0.05）；관찰조 HBV 전음솔위88.3%（53/60），고우대조조적73.3%（44/60）（P ＜0.05）；관찰조 HBeAg 혈청전환솔위13.3%（8/60），저우대조조28.3%（17/60）（P ＜0.05）。결론아덕복위지편결합체비부정치료을간간경화림상효과현저，능유효항병독，차불량반응소。
Objective To investigate the clinical effect and safety of Adefovir Dipivoxil Tablets with telbivudine in the treatment of hepatitis B cirrhosis. Methods 120 cases of patients with hepatitis B cirrhosis from June 2012 to February 2014 treated in our hospital were selected as the research objects,and randomly divided into control group(n = 60)and observation group(n = 60). Then compared the HBV negative rate/ HBeAg serum conversion rate/the liver function/liver fibrosis indexes and the side effect of the two groups. Results After treatment,two groups of the liver function and liver fibrosis indexes were all decreased,and the indexes of the observers reduced significantly than that of control group(P < 0.05); HBV negative rate of observation group was 88.3%(53/60),and significantly higher than that of the control group 73.3%(44/60); HBeAg serum conversion rate of the observation group was 13.3%(8/60), and significantly lower than that of the control group 28.3%(17/60)(P < 0.05). Conclusion Adefovir Dipivoxil Tablets combined with telbivudine play an effective antiviral effect role in the treatment of hepatitis B cirrhosis with little side effect,which is worthy of wide clinical promotion.